Table 3.
Diagnostic testing.
| Overall | SARS‐CoV‐2+ | SARS‐CoV‐2‐ | p | |
|---|---|---|---|---|
| n abnormal/n tested (%) | ||||
| Brain MRI 1 | 9/48 (18.8) | 5/22 (22.7) | 4/26 (15.4) | 0.71 |
| MR Vessel Wall Imaging | 0/4 (0) | 0/2 (0) | 0/2 (0) | 1 |
| Spine MRI 2 | 10/16 (62.5) | 5/8 (62.5) | 5/8 (62.5) | 1 |
| EMG 3 | 3/9 (33) | 1/3 (33) | 2/6 (33) | 1 |
| EEG | 0/4 (0) | 0/3 (0) | 0/1 (0) | 1 |
| CSF analysis 4 | 3/5 (60) | 0/1 (0) | 3/4 (75) | 0.40 |
| Tilt table test | 3/4 (75) | 0 (0) | 3/4 (75) | 1 |
| Antinuclear antibody ≥ 1:160 | 11/33 (33.3) | 3/6 (50) | 8/27 (29.6) | 0.38 |
| Erythrocyte sedimentation rate | ||||
| Median [IQR], Reference: Males: <15 (0‐50 years) or < 20 mm/h (51‐85 years). Females: <20 (0‐50 years) or < 30 mm/h, (51‐85 years). |
8/47 (17) 9 [3‐19] |
2/15 (13.3) 11 [2‐19] |
6/32 (18.8) 8.5 [3.75‐19.5] |
1 |
| C‐reactive protein | ||||
| Median [IQR], Reference: 0.0‐0.5 mg/dL |
10/52 (19.2) 0.5 [0.29‐0.57] |
5/19 (26.3) 0.5 [0.5‐1.2] |
5/33 (15.2) 0.4 [0.24‐0.5] |
0.47 |
| D‐dimer | ||||
| Median [IQR], Reference: 0‐230 ng/mL |
8/27 (29.6) 174.5 [150‐329] |
3/10 (30) 150 [150‐289] |
5/17 (29.4) 215 [163‐327] |
1 |
| Ferritin | ||||
| Median [IQR], Reference: 24‐336 ng/mL |
2/11 (18.2) 75 [42‐120] |
2/5 (40) 105 [42‐120] |
0/6 (0) 65.2 [50.7‐88.5] |
0.18 |
Non‐specific white matter changes (5), microhemorrhage (1), infarction (1), demyelinating disease (1), and schwannoma (1).
Degenerative changes (9) and thecal sac diverticula vs. perineural cysts (1).
Axonal sensory‐predominant polyneuropathy prior to Covid‐19 onset (1), absent medial plantar SNAP (1) due to orthopedic injury, possible S1 radiculopathy (1).
Pleocytosis (1) [12 WBC, 100% lymphocytes], elevated protein (3) (reference) [52 (15‐45), 56 (15‐45), 49 (0‐35)].